CTI BioPharma Corp (NASDAQ:CTIC) announced before US market opened for trading on Monday that the company's experimental drug designed to treat a rare form of blood cancer met its primary endpoint in a pivotal late stage study, sending the shares up 8.3% in pre-market trade, as of the time of the report.
The Seattle, Washington-based biotech reported that Pacritinib proved to be clinically better than the “best available therapies” traditionally prescribed to treat myelofibrosis. The details of the trial, however, will be released at a scientific conference due to be held at a later date.
00:27 Trump warns of ‘retribution’ if companies move jobs out of U.S12
16:38 Swift Energy completes $40 million sale of Louisiana asset10
03:00 Carrier incentives stir debate over 'rewarding' offshoring13
21:23 Princess Cruises to pay record-breaking criminal fine for ocean pollution16